BiotechTube

Pramlintide

ApprovedCompleted
0 watching 0 views this week🔥 Hot
84
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Hypoglycemia

Conditions

Hypoglycemia, Evidence of Previous Gastric Surgery

Trial Timeline

Feb 2, 2010 → Feb 8, 2022

NCT ID
NCT01841359

About Pramlintide

Pramlintide is a approved stage product being developed by Bristol Myers Squibb for Hypoglycemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01841359. Target conditions include Hypoglycemia, Evidence of Previous Gastric Surgery.

Hype Score Breakdown

Clinical
30
Activity
20
Company
9
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT01841359ApprovedCompleted

Competing Products

20 competing products in Hypoglycemia

See all competitors
ProductCompanyStageHype Score
MBX 1416 (INN imapextide)MBX BiosciencesPhase 2
47
MBX 1416 (Part A) + MBX 1416 (Part B) + Placebo + MBX 1416 (Part C)MBX BiosciencesPhase 1
28
Nasal GlucagonEli LillyPhase 3
77
Glucagon + InsulinAbvance TherapeuticsPhase 1
25
Nasal Glucagon + Intramuscular GlucagonEli LillyPhase 1
33
Nasal Glucagon 1 mg + Nasal Glucagon 2 mg + SC Glucagon + Nasal Glucagon 3 mgEli LillyPhase 2
52
Nasal GlucagonEli LillyPhase 3
77
Eplerenone + PlaceboJohnson & JohnsonPre-clinical
23
Sitagliptin phosphate + PlaceboMerckApproved
85
PasireotideNovartisPhase 1
33
DasiglucagonNovo NordiskPhase 3
76
Glucagen + Mayne GlucagonPfizerPhase 1
32
dasiglucagon + placebo + GlucaGen HypoKitZealand PharmaPhase 3
74
Dasiglucagon + PlaceboZealand PharmaPhase 1
30
Dasiglucagon + Dasiglucagon + PlaceboZealand PharmaPhase 2
49
ZP4207 + GlucagonZealand PharmaPhase 1
30
ZP4207 + PlaceboZealand PharmaPhase 1
30
Dasiglucagon + PlaceboZealand PharmaPhase 3
74
dasiglucagon + GlucaGenZealand PharmaPhase 3
74
Dasiglucagon + PlaceboZealand PharmaPhase 2
49

Other Products from Bristol Myers Squibb

DeucravacitinibApproved
84
Aripiprazole + Olanzapine + HaloperidolApproved
84
Irbesartan + CiprofibrateApproved
84
Entecavir + Lamivudine Placebo + Lamivudine + Entecavir PlaceboApproved
84
deucravacitinibApproved
84